A New Approach to Degenerative Disc Disease – Introducing Hydrafil

In this MedInsights Unleashed episode, we explore an emerging treatment for chronic degenerative disc disease called Hydrafil. Our guests are Bill Niland, CEO of ReGelTec Inc., and Dr. Anthony Lowman, PhD, Professor of Biomedical Engineering and Co-Founder/Chief Medical Officer at ReGelTec. They walk us through the science, creation, and development of this injectable hydrogel technology. Hydrafil is designed to help patients with lumbar back pain by restoring hydration and pressure inside the spinal disc, supporting its structure, and potentially reducing inflammation and pain. The episode discusses the challenges of developing a new biomedical device, what the early clinical experience has shown, and the ongoing trials aimed at offering a less invasive option for people living with chronic back pain.  The pivotal study, known as the  ReGelTec has launched the pivotal HYDRAFIL-D Study, a multicenter, randomized, controlled trial enrolling approximately 225 patients across U.S. sites. To follow studies on Hydrafil, visit ClinicalTrials.gov and search: Degenerative Disc Disease + Hydrafil you will finat least two active listings: NCT06011551 (FDA IDE Trial) –NCT04984629 (Calgary, Alberta)